The role of conventional computed tomography (CT) features in assessing response to neoadjuvant therapy for pancreatic ductal adenocarcinoma is limited. Other imaging techniques such as EUS, DWI, PET, and perfusion CT have great potential to assess tumor resectability and predict survival in pancreatic ductal adenocarcinoma after neoadjuvant therapy.